ULTIO Stock Overview
A biotech company, develops immunotherapies against cancers in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ultimovacs ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr7.17 |
| 52 Week High | kr109.00 |
| 52 Week Low | kr100.20 |
| Beta | 1.03 |
| 1 Month Change | -19.71% |
| 3 Month Change | -95.53% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| ULTIO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.5% |
| 1Y | n/a | -20.4% | 6.3% |
Return vs Industry: Insufficient data to determine how ULTIO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ULTIO performed against the UK Market.
Price Volatility
| ULTIO volatility | |
|---|---|
| ULTIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ULTIO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ULTIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 26 | Carlos de Sousa | www.ultimovacs.com |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA Fundamentals Summary
| ULTIO fundamental statistics | |
|---|---|
| Market cap | kr252.88m |
| Earnings (TTM) | -kr177.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs ULTIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ULTIO income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr177.88m |
| Earnings | -kr177.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | -5.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ULTIO perform over the long term?
See historical performance and comparison